Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study

Regorafenib, an oral multikinase inhibitor, has improved survival in metastatic colorectal cancer (mCRC) patients who have progressed on standard therapies. Our study aimed to evaluate prognostic factors influencing regorafenib treatment and assess the optimal dosing regimen in a real-life setting....

Descripción completa

Detalles Bibliográficos
Autores principales: Aydin, Sabin Goktas, Kavak, Engin Eren, Topcu, Atakan, Bayramgil, Ayberk, Akgul, Fahri, Kahraman, Seda, Aykan, Musa Baris, Altıntas, Yunus Emre, Helvaci, Kaan, Urun, Yuksel, Bilici, Ahmet, Seker, Mesut, Nahit Sendur, Mehmet Ali, Olmez, Omer Fatih, Acikgoz, Ozgur, Cicin, Irfan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655877/
https://www.ncbi.nlm.nih.gov/pubmed/37289436
http://dx.doi.org/10.17305/bb.2023.9253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655877/
https://www.ncbi.nlm.nih.gov/pubmed/37289436
http://dx.doi.org/10.17305/bb.2023.9253

Ejemplares similares